Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA known ✓ | P10253 | 2/20 | 0.47 |
| ▸ | KCNH2 known ✓ | Q12809 | 1/20 | 0.46 |
| ▸ | DPP4 known ✓ | P27487 | 1/20 | 0.45 |
| ▸ | MAOB known ✓ | P27338 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 5/20 | 0.49 |
| ▸ | CRHBP | P24387 | 1/20 | 0.49 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | KCNJ1 | P48048 | 1/20 | 0.46 |
| ▸ | MMP2 | P08253 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | MC4R | P32245 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1859938 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTCRHBPCRHR2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL17707255 | 1.00 | ALDH1A1 (0.50) | ALDH1A1MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL1068871 | 0.99 | MAPT (0.50) | ALDH1A1MAPTCRHBPCRHR2L3MBTL1 | |
| SCHEMBL1859542 | 0.99 | MAPT (0.50) | ALDH1A1MAPTCRHBPCRHR2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL6131679 | 0.96 | MAPT (0.48) | ALDH1A1MAPTCRHBPCRHR2L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4371678 | 0.87 | ALDH1A1 (0.64) | ALDH1A1GAAIDO1LMNAMMP2 | |
| Hydrochloric Acid SCHEMBL1230535 | 0.87 | ALDH1A1 (0.64) | ALDH1A1GAAIDO1LMNAMMP2 | |
| Hydrochloric Acid SCHEMBL240404 | 0.87 | ALDH1A1 (0.64) | ALDH1A1GAAIDO1LMNAMMP2 | |
| SCHEMBL4367409 | 0.85 | ALDH1A1 (0.62) | ALDH1A1GAAIDO1LMNAMMP2 | |
| SCHEMBL240405 | 0.85 | ALDH1A1 (0.62) | ALDH1A1GAAIDO1LMNAMMP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4081503-B1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | INDENA SPA (IT) | 2025-07-30 | — | — | EP | disclosed |
| US-12077484-B2 | Process for the synthesis of melphalan | INDENA S.P.A. (IT) | 2024-09-03 | — | — | US | disclosed |
| CN-114845991-B | Method for synthesizing melphalan | 意迪那有限公司 | 2024-05-07 | — | — | CN | disclosed |
| US-11787761-B2 | Process for the synthesis of Melphalan | INDENA S.P.A. (IT) | 2023-10-17 | — | — | US | disclosed |
| US-20230286901-A1 | PROCESS FOR THE SYNTHESIS OF MELPHALAN | INDENA S.P.A. (IT) | 2023-09-14 | — | — | US | disclosed |
| US-20230094970-A1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | INDENA S.P.A. (IT) | 2023-03-30 | — | — | US | disclosed |
| EP-4081503-A1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | Indena S.p.A. (IT) | 2022-11-02 | — | — | EP | disclosed |
| CN-114845991-A | Method for synthesizing melphalan | 因德纳有限公司 | 2022-08-02 | — | — | CN | disclosed |
| CN-114315618-A | Preparation method of synthetic melphalan | 浙江恒腾福生物科技集团有限公司 | 2022-04-12 | — | — | CN | disclosed |
| WO-2021130163-A1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | INDENA S.P.A. (IT) | 2021-07-01 | — | — | WO | disclosed |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | DR. REDDY'S LABORATORIES LIMITED | 2003-12-11 | — | — | US | disclosed |
| WO-2003048116-A2 | ESTERS AND AMIDES AS PPAR-ALPHA AGONISTS ____________ | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-06-12 | — | — | WO | disclosed |
| WO-2003033481-A1 | BENZOXAZINE AND BENZOTHIAZINE DERIVATIVES AND PARMACEUTICAL COMPOSITIONS CONTAINING THEM | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | disclosed |
| WO-2003033456-A1 | NOVEL β-PHENYL-α-OXYSUBSTITUTED PROPIONIC DERIVATIVES: PROCESS FOR ITS PREPARATION AND THEIR USE IN THE PREPARATION OF PHARMACEUTICALLY IMPORTANT COMPOUNDS | DR. REDDY'S LABORATORIES LTD. (IN) | 2003-04-24 | — | — | WO | disclosed |
| US-6420424-B1 | ADMINISTERING PHENYLALANINE AMIDE DERIVATIVES (SUCH AS S-ETHYL-2-AMINO-3-(4-CHLOROPHENYL)PROPIONATE HYDROCHLORIDE) TO TREAT ALLERGIC DISORDERS, INCLUDING ASTHMA, RHINITIS, DERMATITUS, AND PRURITIS | SMITHKLINE BEECHAM CORPORATION | 2002-07-16 | — | — | US | disclosed |
| EP-0638075-B1 | THIAZOLE OR IMIDAZOLE DERIVATIVES AS MAILLARD REACTION INHIBITORS | OTSUKA PHARMA CO LTD (JP) | 2002-01-16 | — | — | EP | disclosed |
| EP-1073434-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 2001-02-07 | — | — | EP | disclosed |
| WO-1999055330-A1 | CCR-3 RECEPTOR ANTAGONISTS | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-04 | — | — | WO | disclosed |
| US-5677322-A | THERAPY FOR AGING, DIABETES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1997-10-14 | — | — | US | disclosed |
| CN-1131418-A | Novel fused-ring carboxylic acid compound or salt thereof, and medicinal use thereof | GREEN CROSS CORP (JP) | 1996-09-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230094970-A1 | A PROCESS FOR THE SYNTHESIS OF MELPHALAN | PAH, IL4I1, TYR | GAA 2338/4885KCNH2 3293/4885DPP4 1884/4885 |
| US-12077484-B2 | Process for the synthesis of melphalan | PAH, TYR, IL4I1 | GAA 2092/4885KCNH2 3038/4885DPP4 1580/4885 |
| US-20030229083-A1 | Compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them | GPR119, LIPA, PCSK9 | GAA 132/4885KCNH2 4226/4885DPP4 23/4885 |
| US-11787761-B2 | Process for the synthesis of Melphalan | PAH, TYR, MARS1 | GAA 2121/4885KCNH2 3038/4885DPP4 1531/4885 |
| US-20230286901-A1 | PROCESS FOR THE SYNTHESIS OF MELPHALAN | PAH, TYR, IL4I1 | GAA 2092/4885KCNH2 3038/4885DPP4 1580/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.